Mirum Pharmaceuticals, Inc.
MIRM
Peringkat dalam Saham
#3313
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Harga Saham
$81.34
Kapitalisasi Pasar
$5.28B
Perubahan (1 hari)
1.49%
Perubahan (1 tahun)
10.61%
Negara
US
Perdagangan Mirum Pharmaceuticals, Inc. (MIRM)
Kategori
Healthcare
EPS untuk Mirum Pharmaceuticals, Inc. (MIRM)
EPS per June 2026 TTM: $-14.56
Menurut laporan keuangan terbaru dan harga saham Mirum Pharmaceuticals, Inc., EPS perusahaan saat ini (TTM) adalah $-14.56. Pada akhir 2023, perusahaan memiliki EPS sebesar $-4.00 penurunan dibandingkan dengan EPS tahun 2022 sebesar $-4.01.
Riwayat EPS untuk Mirum Pharmaceuticals, Inc. dari 2018 hingga 2026
EPS di akhir setiap tahun
| Tahun | EPS | Mengubah |
|---|---|---|
| 2026 (TTM) | $-14.56 | 687.03% |
| 2024 | $-1.85 | -53.75% |
| 2023 | $-4.00 | -0.25% |
| 2022 | $-4.01 | 44.77% |
| 2021 | $-2.77 | -32.27% |
| 2020 | $-4.09 | 78.60% |
| 2019 | $-2.29 | 205.33% |
| 2018 | $-0.75 | 0.00% |
EPS untuk perusahaan sejenis atau pesaing
| Perusahaan | EPS | Perbedaan EPS | Negara |
|---|---|---|---|
| $17.32 | -218.96% |
US
|
|
| $-7.98 | -45.19% |
US
|
|
| $-5.29 | -63.67% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -290.52% |
NL
|
